12:00 AM
 | 
Sep 22, 2008
 |  BC Week In Review  |  Company News  |  Deals

Maxygen, Astellas deal

The partners will co-develop preclinical candidates in Maxygen's MAXY-4 program of second-generation CTLA4-Ig fusion proteins to treat rheumatoid arthritis (RA) and other autoimmune diseases, and Astellas received exclusive, worldwide rights...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >